Notice: This company has been marked as potentially delisted and may not be actively trading. NASDAQ:TRIL Trillium Therapeutics (TRIL) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock Analysis Get Trillium Therapeutics alerts: Email Address About Trillium Therapeutics Stock (NASDAQ:TRIL) 30 days 90 days 365 days Advanced Chart Ad Behind the MarketsThe Standard Oil of AI?ONE AI Stock is All You Need... There are over 6,000 stocks listed in the market right now. They will NOT make you rich. However, there is one stock that stands head and shoulders above everything else. It's currently trading for only $15...Click here for the ticker >>> Get Trillium Therapeutics alerts:Sign Up Key Stats Today's Range$18.44▼$18.4450-Day Range$17.50▼$18.4452-Week Range$5.80▼$20.96Volume8 shsAverage Volume1.87 million shsMarket Capitalization$1.94 billionP/E Ratio29.74Dividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewTrillium Therapeutics, Inc. is a clinical stage immuno-oncology company, which engages in the research and development of therapies for the treatment of cancer. It offers clinical programs, TTI-621 and TTI-622, target CD47, a signal that cancer cells frequently use to evade the immune system. The company was founded on March 31, 2004 and is headquartered in Mississauga, Canada.Read More… The Standard Oil of AI? (Ad)ONE AI Stock is All You Need... There are over 6,000 stocks listed in the market right now. They will NOT make you rich. However, there is one stock that stands head and shoulders above everything else. It's currently trading for only $15...Click here for the ticker >>> Receive TRIL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Trillium Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address TRIL Stock News HeadlinesWhen You Look Back in 5 Years, You'll Wish You'd Bought This $2 Trillion Artificial Intelligence (AI) StockJuly 30, 2024 | finance.yahoo.comLeiomyosarcoma Drug Pipeline Report 2023 - ResearchAndMarkets.comNovember 10, 2023 | businesswire.com10X More Profitable Than Physical Gold?The smart money is piling into gold and gold stocks. There's a backdoor gold play that could deliver 10 TIMES bigger gains than physical gold. That's why I've put together a special presentation on this opportunity...September 27, 2024 | Monument Traders Alliance (Ad)Mirati Therapeutics Stock (NASDAQ:MRTX), Analyst Ratings, Price Targets, PredictionsNovember 8, 2023 | benzinga.comThe Global T-Cell therapy Market size is expected to reach $9.2 billion by 2030, rising at a market growth of 17.5% CAGR during the forecast periodJuly 31, 2023 | uk.finance.yahoo.comWHO Red Flags Punjab-Made Cough Syrup In Fresh Alert: 'Can Cause Even Death'April 26, 2023 | msn.comLeukemia Therapeutics Global Market Report 2023April 4, 2023 | uk.finance.yahoo.comRatio Therapeutics Announces Licensing Agreement for Investigational PET Imaging Agent with MerckMarch 28, 2023 | finance.yahoo.comSee More Headlines TRIL Stock Analysis - Frequently Asked Questions How were Trillium Therapeutics' earnings last quarter? Trillium Therapeutics Inc. (NASDAQ:TRIL) issued its quarterly earnings data on Thursday, November, 18th. The biotechnology company reported ($0.18) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.19) by $0.01. What other stocks do shareholders of Trillium Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Trillium Therapeutics investors own include Inovio Pharmaceuticals (INO), SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), TG Therapeutics (TGTX), Energy Transfer (ET), Gilead Sciences (GILD) and VBI Vaccines (VBIV). Company Calendar Last Earnings11/18/2021Today9/27/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:TRIL CUSIPN/A CIK1616212 Webwww.trilliumtherapeutics.com Phone(416) 595-0627FaxN/AEmployees33Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)$0.62 Trailing P/E Ratio29.74 Forward P/E RatioN/A P/E GrowthN/ANet Income$-59,350,000.00 Net MarginsN/A Pretax Margin-113,720.92% Return on Equity-23.31% Return on Assets-18.66% Debt Debt-to-Equity RatioN/A Current Ratio19.82 Quick Ratio19.82 Sales & Book Value Annual Sales$150,000.00 Price / Sales12,907.39 Cash FlowN/A Price / Cash FlowN/A Book Value$2.56 per share Price / Book7.20Miscellaneous Outstanding Shares104,995,000Free Float95,440,000Market Cap$1.94 billion OptionableOptionable Beta2.08 Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report This page (NASDAQ:TRIL) was last updated on 9/27/2024 by MarketBeat.com Staff From Our PartnersThe Bible Says it Clear As DayIt came to me clear-as-day thanks to the Bible… in the Parable of Talents, in the book of Matthew… This pa...Prosperity Research | Sponsored10X More Profitable Than Physical Gold?The smart money is piling into gold and gold stocks. There's a backdoor gold play that could deliver 10 TIM...Monument Traders Alliance | SponsoredPrepare for an election day stock surpriseDuring his 50 years on Wall Street, legendary stockpicker Marc Chaikin traded through 13 presidential election...Chaikin Analytics | SponsoredBuffett Dumps $982 Million in BofA Stock—What Does He Know?Buffett's been eerily quiet about his reasons, but his actions speak volumes. When someone with his track reco...Genesis Gold Group | SponsoredKamala’s Dirty Election Move… RevealedAccording to former advisor to the CIA, the Pentagon and the White House Jim Rickards… Kamala and her puppe...Paradigm Press | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | SponsoredNvidia is Pivoting to Solve Big Tech’s $1 Trillion ProblemTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | SponsoredFed Triggers Boom: Buy this Play on Elon’s New AIHave you seen Elon Musk's new invention? I was already very bullish on this new type of AI. And now that...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Trillium Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Trillium Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
